Compare
Nexgel, Inc. vs Profound Medical Corp. vs Vivos Therapeutics, Inc. vs INVO Fertility, Inc.
| Latest fiscal year | Nexgel, Inc. NXGL | Profound Medical Corp. PROF | Vivos Therapeutics, Inc. VVOS | INVO Fertility, Inc. IVF |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $11.42M | $16.10M | $17.44M | $6.84M |
| Revenue growth (YoY) | +31.5% | +50.7% | +16.0% | +4.7% |
| Gross margin | 39.5% | 70.8% | 60.4% | n/a |
| Operating margin | -29.3% | -256.3% | -114.1% | -105.8% |
| Net margin | -26.3% | -264.4% | -121.4% | -340.9% |
| Net income | -$3.00M | -$42.57M | -$21.17M | -$23.32M |
| EPS (Diluted) | -$0.38 | $1.41 | -$2.07 | -$214.64 |
| Operating cash flow | -$1.31M | -$38.21M | -$15.26M | -$7.01M |
| Free cash flow | -$1.38M | -$38.38M | -$17.60M | -$7.06M |
| Cash & equivalents | n/a | $59.72M | $2.03M | n/a |
| Total assets | $10.46M | $77.47M | $25.15M | $20.22M |
| Total liabilities | $5.57M | $11.04M | $26.70M | $13.00M |
| Shareholders' equity | $4.46M | $66.43M | -$1.49M | $7.22M |
| Return on year-end equity | -67.3% | -64.1% | n/a | -322.8% |
| Shares outstanding | 8.14M | 36.29M | 9.29M | 477.4K |
Revenue, most recent five fiscal years
| Fiscal year | Nexgel, Inc. | Profound Medical Corp. | Vivos Therapeutics, Inc. | INVO Fertility, Inc. |
|---|---|---|---|---|
| Latest | $11.42M Ended 2025-12-31 | $16.10M Ended 2025-12-31 | $17.44M Ended 2025-12-31 | $6.84M Ended 2025-12-31 |
| 1 year earlier | $8.69M Ended 2024-12-31 | $10.68M Ended 2024-12-31 | $15.03M Ended 2024-12-31 | $6.53M Ended 2024-12-31 |
| 2 years earlier | $4.09M Ended 2023-12-31 | $7.20M Ended 2023-12-31 | $13.80M Ended 2023-12-31 | $3.02M Ended 2023-12-31 |
| 3 years earlier | $2.05M Ended 2022-12-31 | n/a | $16.02M Ended 2022-12-31 | n/a |
| 4 years earlier | $1.55M Ended 2021-12-31 | n/a | $16.89M Ended 2021-12-31 | n/a |